GlassScriptPhysician profile
Beata V Dobson
NPI 1699161265
$2,645.09
in general payments reported to CMS, 2019-2025
19 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $555 · 2022: $768 · 2023: $370 · 2024: $681 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $493.88 | 2022-2025 | Wegovy |
| Neurelis, INC. | $235.97 | 2021-2024 | Valtoco |
| Abbvie INC. | $193.32 | 2022-2023 | |
| Abiomed | $145.40 | 2025 | |
| Janssen Pharmaceuticals, INC | $136.56 | 2024 | Spravato |
| Celltrion USA INC. | $134.72 | 2024 | Zymfentra |
| Genzyme Corporation | $125.01 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $124.99 | 2022 | |
| Dexcom, INC. | $122.42 | 2022 | |
| Gilead Sciences, INC. | $119.99 | 2024 | Epclusa |
| Neurocrine Biosciences, INC. | $112.58 | 2021 | |
| Csl Behring | $112.54 | 2024 | Hizentra |
| Incyte Corporation | $109.99 | 2022 | |
| Avanir Pharmaceuticals, INC. | $109.11 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $93.55 | 2022 | |
| Biogen, INC. | $90.00 | 2021 | |
| Mylan Specialty L.P. | $31.21 | 2024 | Yupelri |
| Boston Scientific Corporation | $28.85 | 2024 | Spyglass Discover |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beata Dobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.